At Paragon, we are proud to address the critical needs of the Alzheimer’s Disease community by providing early-stage patients with LEQEMBI® (lecanemab-irmb) at our infusion centers nationwide.
We know the importance of LEQEMBI®’s full FDA approval, and stand ready to support the infusion access needs of our patients covered under Medicare and all major commercial plans.